OUR PIPELINE
| REGIMEN | Disease | Preclinical | Phase 1 | Phase 2 | Phase 3 | Registration Status | Learn More |
|---|---|---|---|---|---|---|---|
| Ublituximab: glycoengineered anti-CD20 mAb | Relapsing MS |
ULTIMATE I and II
|
APPROVED 12/28/2022 |
 |
|||
| Ublituximab: glycoengineered anti-CD20 mAb | Relapsing MS |
ENHANCE
|
|
||||
| Azer-Cel: CD19 directed allogeneic CAR-T | B-cell disorders | |
|||||
| TG-1801: anti-CD47/CD19 bispecific mAb | B-cell disorders | |
|||||
| TG-1701: BTK inhibitor | B-cell disorders | |
|||||
The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.
| REGIMEN | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|---|---|
|
|
Ublituximab: glycoengineered anti-CD20 mAb
DiseaseRelapsing MS Learn More |
ULTIMATE I and II
APPROVED 12/28/2022 |
|||
|
|
Ublituximab: glycoengineered anti-CD20 mAb
DiseaseRelapsing MS Learn More |
ENHANCE
|
|||
|
|
Azer-Cel: CD19 directed allogeneic CAR-T
DiseaseB-cell disorders Learn More |
||||
|
|
TG-1801: anti-CD47/CD19 bispecific mAb
DiseaseB-cell disorders Learn More |
||||
|
|
TG-1701: BTK inhibitor
DiseaseB-cell disorders Learn More |
||||
|
The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.
|
||||||